{"nct_id":"NCT05201066","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2023-02-13","start_date_type":"ACTUAL","primary_completion_date":"2028-02-14","primary_completion_date_type":"ESTIMATED","completion_date":"2028-02-14","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["NVS"]}